Guizhou Sanli Pharmaceutical Co Ltd is a China-based company primarily engaged in the research, development, production, and sales of pharmaceuticals. The products primarily include respiratory medications, tonics, gynecological medications, orthopedic medications, and cardiovascular medications. The specific pharmaceutical products include Kaihoujian Spray (children's version), Kaihoujian Spray, Qijiao Shengbai Capsules, Fuke Zaizao Pills, Zhike Huatan Pills, Huangqi Granules, and Qiangli Tianma Duzhong Capsules. The Company distributes its products within the domestic market.

Employees

1,887

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
25/06/26	CN¥13.99	-4.96%	14,323,300
24/06/26	CN¥14.72	-0.88%	13,854,000
23/06/26	CN¥14.85	-3.76%	17,286,900
22/06/26	CN¥15.43	-1.34%	17,833,200
18/06/26	CN¥15.64	+3.30%	19,687,200

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 25/06/2026			5-day change	1st Jan Change
13.99 ^CNY	-4.96%		-10.55%	+19.57%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE

Market Cap	5.66B 833M 732M 674M 630M 1.18B 78.62B 1.2B 8.09B 3.13B 38.76B 3.13B 3.06B 135B	P/E 2024	19.4x	P/E 2025	106x
Enterprise Value	6.01B 884M 777M 716M 669M 1.26B 83.46B 1.28B 8.59B 3.33B 41.14B 3.32B 3.25B 143B	EV / Sales 2024	2.48x	EV / Sales 2025	2.99x
Free-Float	40.74%	Yield 2024	2.62%	Yield 2025	0.51%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE
05-25	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 700 million in funding	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 300 million in funding	CI
12-03	Sanli Pharma to Withdraw Stake in Associate; Shares Down 3%	MT
27/10/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
12/09/25	Tranche Update on Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on September 13, 2024.	CI
11/09/25	Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback announced on September 12, 2024, has closed with 7,869,300 shares, representing 1.93% for CNY 99.95 million.	CI
27/08/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
23/04/25	Guizhou Sanli Pharmaceutical Co.,Ltd announces Annual dividend, payable on June 26, 2025	CI
22/04/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

1 day	-4.96%
1 week	-10.55%
Current month	-14.07%
1 month	-5.22%
3 months	+29.54%
6 months	+17.86%
Current year	+19.57%

GuiZhou SanLi Pharmaceutical Co.,Ltd Stock

Stocks

603439

CNE1000040B4

Pharmaceuticals

Valuation: GuiZhou SanLi Pharmaceutical Co.,Ltd

Chart: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest news : GuiZhou SanLi Pharmaceutical Co.,Ltd

Quotes and Performance

Course Extremes

Managers and Directors: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	13.89	16.25
1 month	13.41	17.46
Current year	10.49	17.46
1 year	10.49	17.46
3 years	10.49	20.34
5 years	10.49	21.28
10 years	8.82	44.1

Manager	Title	Age	Since
Qian Fan Zhang CEO	Chief Executive Officer	41	27/05/2024
Hai Zhang CEO	Chief Executive Officer	41	01/09/2011
Ke Guo DFI	Director of Finance/CFO	39	01/11/2024

Director	Title	Age	Since
Hai Zhang CHM	Chairman	41	01/03/2018
Qian Fan Zhang BRD	Director/Board Member	41	01/03/2018
Yong Jian Sheng BRD	Director/Board Member	52	28/01/2015

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/09/24	Hai Zhang	Sell	Chief Executive Officer	21,000,000	5.1428%
02/08/24	Jue Ben Wang	Buy	Director	13,000	0.0032%
05/08/23	Yuan Yu	Sell		25,000	0.0061%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIZHOU SANLI PHARMACEUTICAL CO.,LTD	-4.96%	-10.55%	+16.78%	-15.16%	833M
ELI LILLY AND COMPANY	+0.93%	+2.65%	+42.33%	+145.77%	1,006B
JOHNSON & JOHNSON	+1.61%	+7.22%	+60.81%	+47.98%	589B
ABBVIE INC.	+3.51%	+12.31%	+31.15%	+78.88%	430B
ROCHE HOLDING AG	+0.99%	+5.11%	+29.26%	+21.27%	331B
ASTRAZENECA PLC	+1.09%	+6.90%	+37.22%	+23.11%	288B
NOVARTIS AG	+1.34%	+6.74%	+32.63%	+38.93%	285B
NOVO NORDISK A/S	+1.32%	+12.69%	-27.48%	-42.00%	213B
AMGEN INC.	+0.40%	+4.51%	+25.85%	+55.35%	190B
GILEAD SCIENCES, INC.	-1.05%	+0.06%	+16.91%	+59.86%	154B
Average	+0.52%	+4.31%	+26.55%	+41.40%	348.66B
Weighted average by Cap.	+1.32%	+5.37%	+35.33%	+70.08%

	2024	2025
Net sales	2.14B 316M 277M 255M 239M 448M 29.77B 456M 3.06B 1.19B 14.68B 1.18B 1.16B 51.01B	1.7B 251M 220M 203M 190M 356M 23.64B 362M 2.43B 942M 11.65B 941M 920M 40.5B
Net income	274M 40.32M 35.42M 32.63M 30.51M 57.23M 3.8B 58.28M 392M 152M 1.88B 151M 148M 6.52B	46.25M 6.81M 5.98M 5.51M 5.15M 9.66M 642M 9.84M 66.09M 25.6M 317M 25.56M 25M 1.1B
Net Debt	108M 15.84M 13.92M 12.82M 11.99M 22.48M 1.49B 22.9M 154M 59.59M 737M 59.49M 58.19M 2.56B	349M 51.31M 45.07M 41.53M 38.83M 72.82M 4.84B 74.16M 498M 193M 2.39B 193M 188M 8.29B